<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440166</url>
  </required_header>
  <id_info>
    <org_study_id>CAT-1004-101</org_study_id>
    <nct_id>NCT01440166</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers</brief_title>
  <official_title>A Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catabasis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catabasis Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the safety and tolerability of escalating single doses of CAT-1004 relative
           to placebo in healthy adult volunteers.

        -  To evaluate the pharmacokinetics (PK) of escalating single doses of CAT-1004 in healthy
           adult volunteers.

        -  To evaluate the effect of a high-fat meal on single doses of CAT-1004 in healthy adult
           volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Change from Baseline versus Day-1 though 72 hrs post dose and EOT/FU</time_frame>
    <description>Safety Endpoints: Laboratory evaluations including hematology, chemistry, coagulation and urinalysis, physical examinations, AEs, serious AEs (SAEs), ECGs, and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>Plasma blood samples through 72 hrs, urine collections through 48 hrs</time_frame>
    <description>The following noncompartmental PK parameters will be calculated: area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf), area under concentration-time curve from time 0 to time of last quantifiable concentration (AUClast), maximum observed plasma concentration (Cmax), time to first occurrence of Cmax (Tmax), terminal phase elimination half-life (tÂ½), apparent oral clearance (CL/F), and volume of distribution during the terminal phase (Vz/F). Additional PK parameters may be calculated if deemed appropriate.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 / Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose orally: CAT-1004 Dose level 1 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 / Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose orally: CAT-1004 Dose level 2 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 /Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose orally: CAT-1004 Dose level 3 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4/ Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose orally: CAT-1004 Dose level 4 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5/ Dose level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose orally: CAT-1004 Dose level 5 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2/ Dose level 2 ( FE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose orally (Under fed conditions): CAT-1004 Dose level 2 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3/ Dose level 3 (FE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose orally (Under fed conditions): CAT-1004 Dose level 3 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6 / Dose level 6 (FE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose orally (Under fed conditions) CAT-1004 Dose level 4 or placebo Subjects may be reenrolled from Cohort 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 / Dose level 7 (FE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose orally (Under fed conditions)CAT-1004 Dose level 5 or placebo Subjects may be reenrolled from Cohort 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug</intervention_name>
    <description>Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.</description>
    <arm_group_label>Cohort 1 / Dose level 1</arm_group_label>
    <arm_group_label>Cohort 2 / Dose level 2</arm_group_label>
    <arm_group_label>Cohort 3 /Dose level 3</arm_group_label>
    <arm_group_label>Cohort 4/ Dose level 4</arm_group_label>
    <arm_group_label>Cohort 5/ Dose level 5</arm_group_label>
    <arm_group_label>Cohort 2/ Dose level 2 ( FE)</arm_group_label>
    <arm_group_label>Cohort 3/ Dose level 3 (FE)</arm_group_label>
    <arm_group_label>Cohort 6 / Dose level 6 (FE)</arm_group_label>
    <arm_group_label>Cohort 7 / Dose level 7 (FE)</arm_group_label>
    <other_name>CAT-1004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.</description>
    <arm_group_label>Cohort 1 / Dose level 1</arm_group_label>
    <arm_group_label>Cohort 2 / Dose level 2</arm_group_label>
    <arm_group_label>Cohort 3 /Dose level 3</arm_group_label>
    <arm_group_label>Cohort 4/ Dose level 4</arm_group_label>
    <arm_group_label>Cohort 5/ Dose level 5</arm_group_label>
    <arm_group_label>Cohort 2/ Dose level 2 ( FE)</arm_group_label>
    <arm_group_label>Cohort 3/ Dose level 3 (FE)</arm_group_label>
    <arm_group_label>Cohort 6 / Dose level 6 (FE)</arm_group_label>
    <arm_group_label>Cohort 7 / Dose level 7 (FE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. In good health.

          2. Age: 19 to 55 years inclusive at Screening.

          3. Satisfies one of the following

               -  Females not of childbearing potential: non-pregnant and non-lactating; surgically
                  sterile or postmenopausal, OR

               -  Males: surgically sterile, abstinent, or subject or partner is utilizing an
                  acceptable contraceptive method during and 3 months after the last study dose.

          4. BMI: 18 to 30 kg/m2 at Screening.

        Key Exclusion Criteria:

          1. Clinically significant abnormalities in physical examination or vital signs.

          2. Clinically significant electrocardiogram (ECG) abnormalities as assessed by the
             investigator.

          3. Clinically significant screening laboratory result as assessed by the Investigator.

          4. The subject has a history of clinically significant allergies (except for untreated,
             asymptomatic seasonal allergies at the time of dosing), or hematological, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or neurological
             disease.

          5. History or presence of malignancy with the past 5 years.

          6. History of alcohol or substance abuse or eating disorder within 2 years, OR regular
             use of alcohol within 6 months (&gt;14 units of alcohol per week; 1 unit = 150 mL of
             wine, 360 mL of beer, or 45 mL of 40% alcohol).

          7. Use of any investigational drug or participation in any investigational study within
             30 days prior to screening. For dose levels 6 and 7 fed cohorts, subjects may
             participate who have taken part in the dose levels 4 and 5 fasted cohort.

          8. Any significant blood loss within 60 days prior to screening, e.g. blood donation,
             participation in study with multiple blood draws, etc.

          9. Any condition, disease, disorder or clinically relevant laboratory abnormality that,
             in the opinion of the Investigator, would jeopardize the subject's appropriate
             participation in this study or obscure the effects of treatment.

         10. A suspected allergy or sensitivity to CAT-1004 or excipients based upon known
             allergies to excipients or compounds of a similar class.

         11. Any clinically significant systemic infection within 3 weeks prior to screening.

         12. Use of prescription medications within 30 days of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Rasmussen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion Clinical Research Unit</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

